A biotech startup has been exploring brainless human clones for years. This could reshape longevity markets and healthcare investing.

The Big Picture R3 Bio operated in stealth until last week. The Richmond, California startup announced it raised money to create nonsentient monkey "organ sacks" as an alternative to animal testing. But internal documents reveal a broader vision: brainless human clones to serve as backup bodies.

Founder John Schloendorn has pitched this idea in private circles. He's shown medical scans of children with birth defects missing most cortical hemispheres as evidence a body can live without much brain.

“"The team reserves the right to hold hypothetical futuristic discussions," cofounder Alice Gilman said when pressed about brainless clones.”

Why It Matters Longevity biotech attracts aggressive venture capital. **Three investors back R3 Bio**: billionaire Tim Draper, Singapore-based fund Immortal Dragons, and life-extension investors LongGame Ventures. These players seek transformative returns, not incremental ones.

Schloendorn and Gilman presented at Abundance Longevity, a $70,000-per-ticket event in Boston. The "Full Body Replacement" session discussed personal clones for spare organs according to an attendee. This suggests high-net-worth investors are funding frontier concepts.

The startup insists "any allegations of intent or conspiracy to create human clones or humans with brain damage are categorically false." But its 2023 technical roadmap describes "body replacement cloning." This disconnect between public and private messaging is common in cutting-edge biotech.

The Bottom Line Watch how R3 Bio's narrative evolves. If the startup progresses to non-human primate trials, it could unlock new valuation. But regulatory and reputational risk is extreme. Longevity investors are betting on speculative science; this might be the boldest wager yet.